EGFR and breast cancer: For instance, in a multicenter randomized trial (NCT01619111), an analysis of the effectiveness of lapatinib (an anti-HER2/EGFR drug) is performed in metastatic, initially HER2-negative BC patients with HER2-positive CTCs.